Skip to main content
Evidence Snapshot

Human alphaherpesvirus 1

CHEMBL377 ORGANISM Human alphaherpesvirus 1
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:02Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL377
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Human alphaherpesvirus 1 as ChEMBL target CHEMBL377. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Human alphaherpesvirus 1
ORGANISM · Human alphaherpesvirus 1
As of 2026-09-14
ChEMBL target ID
CHEMBL377
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Human alphaherpesvirus 1 matters

As of 2026-09-14

Human alphaherpesvirus 1 is reviewed as Human alphaherpesvirus 1; the current evidence base includes 22 approved drugs, 5991 compounds, and 1779 assays, with lead potency reaching pChEMBL 10.6.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 22 approved drugs, 5991 compounds, and 1779 assays for this target. The dominant activity type is EC50. CHEMBL484 is the current potency anchor at pChEMBL 10.6.

Use CHEMBL484 as the tractability anchor when discussing potency (pChEMBL 10.6).

Activity source · ChEMBL 36 via Core Engine
22 approved pChEMBL 10.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Human alphaherpesvirus 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5991
Total Compounds
1779
Total Assays
22
Approved Drugs
IC50: 1523.0, KI: 10.0, EC50: 3312.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL484
 10.6 IC50 Clinical
No preferred name
CHEMBL298845
 10.6 IC50 —
No preferred name
CHEMBL504793
 10.6 IC50 —
No preferred name
CHEMBL301240
 10.3 IC50 —
No preferred name
CHEMBL57548
 10.0 IC50 —

Approved Drugs

Structure Compound First Approval
PALBOCICLIB
CHEMBL189963
 2015
ADEFOVIR DIPIVOXIL
CHEMBL922
 2002
PENCICLOVIR
CHEMBL1540
 1996
CIDOFOVIR
CHEMBL5314375
 1996
PODOFILOX
CHEMBL61
 1990
GANCICLOVIR
CHEMBL182
 1989
ACYCLOVIR
CHEMBL184
 1982
CICLOPIROX
CHEMBL1413
 1982
CYTARABINE
CHEMBL803
 1969
IDOXURIDINE
CHEMBL788
 1963
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:02Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL377